For patients with HbA1c >6 can the INAVO regimen still be utilized if the patient is otherwise fit and has a strategy for ongoing glycemic control?

Hyperglycemia is a common and significant side effect for PIK3CA inhibitors such as inavolisib. I do believe the INAVO regimen can be utilized in patients with diabetes on a case-by-case basis, with the recognition that a comprehensive management plan including diet, medications, and endocrinology s...

The INAVO120 trial excluded patients with fasting glucose levels ≥126 mg/dL or HbA1c ≥6.0%. This exclusion was due to the known risk of hyperglycemia associated with PI3K inhibitors. Therefore, the safety and efficacy of inavolisib in patients with HbA1c >6.0% have not been prospectively established...